Background: Although incidence rates of breast cancer molecular subtypes are well documented, effects of molecular subtypes on breast cancer-specific survival using the largest population coverage to date are unknown in the U. Population: Methods: Using Surveillance, Epidemiology and End Results cancer registry data, we assessed survival after breast cancer diagnosis among women diagnosed during to and followed through December 31, Multiple imputation was used to fill in missing receptor status. A Cox proportional hazards model was used to evaluate survival while controlling for clinical and demographic factors. Notably, failing to impute cases with missing receptor status leads to overestimation of survival because those with missing receptor status tend to have worse prognostic features.
The Who, What, Where, When and Sometimes, Why.
Understanding Breast Cancer Survival Rates
Skip to Content. You will also read general information on surviving the disease. Remember, survival rates depend on several factors. Use the menu to see other pages. The disease typically occurs in women younger than Black women seem to have a higher risk of inflammatory breast cancer than white women. Because inflammatory breast cancer can grow and spread quickly, this cancer often spreads to the lymph nodes around the breast.
Survival Rates for Breast Cancer
Breast cancer is the most common cancer in the UK. Survival for breast cancer is generally good, particularly if you are diagnosed early. This is probably because of screening, early diagnosis and improved treatment.
Questions about the survival rate and recurrence rate are very common when someone is diagnosed with triple-negative breast cancer TNBC. While prognosis is, on average, poorer than with hormone receptor or human epidermal growth factor receptor 2 HER2 positive tumors, triple-negative breast cancer is a very heterogeneous diverse disease. On a positive note, and unlike hormone-positive tumors that commonly recur late after five years , late recurrence is less common with triple-negative tumors. The recent approval of immunotherapy only for triple-negative disease is also optimistic. We will look at factors that may affect survival or recurrence as well as the statistical rates of both.